Company / Accounts Receivable
Arcadia Biosciences, Inc. Accounts Receivable History
FY2016-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$1.4M
FY2021
5-year range
$1.4M / $1.4M
FY2017-FY2021
Trend
-2.6%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 6 years, ranging from $165,000 in FY2018 to $1M in FY2020.
Based on SEC 10-K filings.
$1M in FY2021 with a 5-year CAGR of +31.5%.
Improved from $602,000 to $1M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +102.5%
- 5-Year CAGR
- +31.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +31.5%, indicating consistent growth.
- In FY2021, accounts receivable decreased 2.6% year-over-year.
- Peak accounts receivable was recorded in FY2020.
- Lowest accounts receivable in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 7.60 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $1.4M | -2.6% |
| FY2020 | $1.4M | +133.6% |
| FY2019 | $602.0K | +264.8% |
| FY2018 | $165.0K | -86.6% |
| FY2017 | $1.2M | +252.7% |
| FY2016 | $349.0K | -50.6% |
As of FY2021 · SEC 10-K · Updated Jun 28, 2026